Crinetics Pharmaceuticals Completes $10B Merger, Becomes Wholly Owned Subsidiary

What Happened
Crinetics Pharmaceuticals, Inc. filed an 8-K on September 1, 2026 announcing that the previously disclosed merger (per the July 6, 2026 merger agreement) was consummated. As a result, Crinetics became a wholly owned subsidiary of the acquiring parent (Vertex Pharmaceuticals), and the aggregate consideration paid in the merger was approximately $10.0 billion. Immediately prior to and at the Effective Time/Closing Date the company took several corporate actions tied to the transaction.

Key Details

• Aggregate merger consideration: approximately $10.0 billion, funded with a combination of Parent cash and borrowings under Parent’s term loan.
• Corporate actions effective at the Effective Time/Closing Date:
  • All outstanding shares of Crinetics common stock converted into the right to receive the merger consideration; former stockholders ceased to have stockholder rights other than the right to receive that consideration.
  • Trading of Crinetics common stock was suspended and the company requested Nasdaq to file a Form 25 to delist and deregister the shares; the company intends to file Form 15 to terminate registration under Section 12(g) and suspend SEC reporting.
  • The company’s certificate of incorporation and bylaws were amended and restated (filed as Exhibits 3.1 and 3.2).
  • Several equity plans and agreements were terminated, including the 2018 Employee Stock Purchase Plan, the 2018 Incentive Award Plan, the 2015 Stock Incentive Plan, the 2021 Employment Inducement Incentive Award Plan, and the June 21, 2024 Sales Agreement with SVB Leerink LLC and Cantor Fitzgerald & Co.
  • Board and management changes: all prior directors (listed in the filing) resigned; Charles Wagner (former sole director of Merger Sub) became sole director of the surviving corporation; Charles Wagner, Prasanna Thombre and Omar White became President, Treasurer and Secretary, respectively, and all incumbent officers were removed.

Why It Matters
For investors, this 8-K documents a completed change of control: Crinetics is no longer a publicly traded independent company and its shareholders received the merger consideration in exchange for their shares. Delisting and deregistration steps mean Crinetics’ stock will be removed from Nasdaq and the company will suspend SEC reporting obligations, ending the public reporting and trading regime for Crinetics common stock. The filing also records governance and compensation-plan changes that follow from the merger and the new ownership structure.